Market Place
Sourcing Support
Lilly changes lead psoriasis program from $2.4B Dice buyout
30 Oct 2024 //
FIERCE BIOTECH
Lilly Completes Acquisition of DICE Therapeutics
09 Aug 2023 //
PR NEWSWIRE
Lilly Announces Extension of Tender Offer to Acquire DICE
25 Jul 2023 //
PR NEWSWIRE
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
21 Jun 2023 //
PRESS RELEASE
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
13 Jun 2023 //
GLOBENEWSWIRE
DICE Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
DICE Therapeutics to Participate in the Bank of America 2023 Conference
03 May 2023 //
GLOBENEWSWIRE
DICE Therapeutics to Participate in the H.C. Wainwright Virtual Conference
23 Mar 2023 //
GLOBENEWSWIRE
DICE Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 (AAD)
01 Mar 2023 //
GLOBENEWSWIRE
DICE Therapeutics to Participate at Upcoming Investor Conferences
08 Feb 2023 //
GLOBENEWSWIRE
DICE Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
DICE Therapeutics Reports 3Q 2022 Financial Results and Recent Highlights
09 Nov 2022 //
GLOBENEWSWIRE
DICE Therapeutics to Present at Upcoming Investor Conferences
03 Nov 2022 //
GLOBENEWSWIRE
DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise
17 Oct 2022 //
GLOBENEWSWIRE
Now with positive PhI data, DICE goes after public offering in search of $250M
12 Oct 2022 //
ENDPTS
DICE rolls on as lead oral IL-17 candidate meets proof-of-concept in PhI tria
11 Oct 2022 //
ENDPTS
DICE Announces Proposed Public Offering of Common Stock
11 Oct 2022 //
GLOBENEWSWIRE
You might want to take a look at DICE Therapeutics Inc. (DICE) now
13 Sep 2022 //
SETENEWS
DICE Therapeutics Reports Q2 2022 Rusult and Recent Highlights
11 Aug 2022 //
GLOBENEWSWIRE
DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical
21 Jul 2022 //
GLOBENEWSWIRE
DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
DICE Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
03 May 2022 //
GLOBENEWSWIRE
DICE Therapeutics Expands Management Team and Board of Directors
28 Mar 2022 //
GLOBENEWSWIRE
DICE Therapeutics Reports Q4 and Full Year 2021 Financial Results
21 Mar 2022 //
GLOBENEWSWIRE
DICE Therapeutics to Present at the 11th Annual SVB Leerink Conference
10 Feb 2022 //
GLOBENEWSWIRE
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
16 Nov 2021 //
FIERCEBIOTECH
DICE Therapeutics up 84% following upsized IPO
15 Sep 2021 //
SEEKINGALPHA
Kevin Judice plays DiCE, pivoting from a $60M raise
27 Aug 2021 //
ENDPTS
DiCE Molecules Announces $60 Million Series C-1 Financing
24 Aug 2021 //
BUSINESSWIRE
